# Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer

> **NCT00532623** · PHASE2 · COMPLETED · sponsor: **National Cancer Center, Korea** · enrollment: 82 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Gemcitabine plus Vinorelbine
- **DRUG:** Sequential

## Key facts

- **NCT ID:** NCT00532623
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-09
- **Final completion:** 2006-10
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2011-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532623, "Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00532623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*